• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 10, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

A new role for an old protein in breast cancer

Bioengineer.org by Bioengineer.org
January 19, 2018
in Headlines, Health, Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of Kent

Scientists led by Dr Chris Toseland of the University's School of Biosciences studied a protein called Myosin VI, a molecular motor which acts as a courier to transport other proteins within our cells. Myosin VI is highly present in many cancers yet the role is unclear. Dr Toseland's study to understand the role of Myosin VI found it was critical in the production of specific genes which are linked to cell growth and tumour development. This is particularly relevant to breast, ovarian, prostate and colon cancer.

Approximately 70% of all breast cancer is oestrogen sensitive and the results of this study may identify new treatment targets for patients with the disease. As a result of his findings, Dr Toseland is now inviting patients in the NHS to take part in further research. This will investigate how myosins are targeted to specific genes, and determine how they are themselves regulated, enhancing scientists understanding of their function during breast cancer.

Understanding the role of Myosin VI in the disease may also highlight further diagnostic clues for the disease. This would potentially allow for a better choice of treatment to be administered.

Dr Toseland's findings are presented in an article entitled: NDP52 activates nuclear myosin VI to enhance RNA polymerase II transcription, published in the journal Nature Communications.

###

For further information or interview requests contact Sandy Fleming at the University of Kent Press Office. Tel: 01227-823581/01634-888879 Email: [email protected]

News releases can also be found at http://www.kent.ac.uk/news

University of Kent on Twitter: http://twitter.com/UniKent

Notes to Editors

https://www.nature.com/articles/s41467-017-02050-w Nuclear Myosin VI – a therapeutic target in oestrogen receptor positive breast cancer? aims to recruit 100 patients with oestrogen receptor positive breast cancer and 20 patients who do not have breast cancer as a comparison group. The University of Kent will provide the initial funding of the study and applications for funding have been made to major UK Breast Cancer Charities.

Transfer of the genetic code (gene expression) into cellular proteins is one of the most fundamental processes in living cells and is orchestrated by protein-based molecular machines. Cells have evolved elaborate regulation mechanisms to control these molecular machines. It is a breakdown in this regulation that leads to diseases such as cancer.

Established in 1965, the University of Kent – the UK's European university – now has almost 20,000 students across campuses or study centres at Canterbury, Medway, Tonbridge, Brussels, Paris, Athens and Rome.

It has been ranked 22nd in the Guardian University Guide 2018 and 25th in the Complete University Guide 2018, and in June 2017 was awarded a gold rating, the highest, in the UK Government's Teaching Excellence Framework (TEF).

In the Times Higher Education (THE) World University Rankings 2015-16, it is in the top 10% of the world's leading universities for international outlook and 66th in its table of the most international universities in the world. The THE also ranked the University as 20th in its 'Table of Tables' 2016.

Kent is ranked 17th in the UK for research intensity (REF 2014). It has world-leading research in all subjects and 97% of its research is deemed by the REF to be of international quality.

In the National Student Survey 2016, Kent achieved the fourth highest score for overall student satisfaction, out of all publicly funded, multi-faculty universities.

Along with the universities of East Anglia and Essex, Kent is a member of the Eastern Arc Research Consortium .

The University is worth £0.7 billion to the economy of the south east and supports more than 7,800 jobs in the region. Student off-campus spend contributes £293.3m and 2,532 full-time-equivalent jobs to those totals.

Kent has received two Queen's Anniversary prizes for Higher and Further Education.

Media Contact

S.Fleming
[email protected]
44-012-278-23581
@UniKent

http://www.kent.ac.uk

Related Journal Article

http://dx.doi.org/10.1038/s41467-017-02050-w

Share12Tweet7Share2ShareShareShare1

Related Posts

miRNAs: Key Players in Lung Cancer Transition

September 10, 2025

Neuronal Activity Drives Small Cell Lung Cancer

September 10, 2025

CRISPR-Cas9: Transforming Crop Improvement Journey

September 10, 2025

Wertheim UF Scripps Scientists Receive $15.7 Million in New Research Grants

September 10, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    61 shares
    Share 24 Tweet 15
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

miRNAs: Key Players in Lung Cancer Transition

Neuronal Activity Drives Small Cell Lung Cancer

CRISPR-Cas9: Transforming Crop Improvement Journey

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.